(Circulation. 1996;94:2807-2816.)
© 1996 American Heart Association, Inc.
Articles |
Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure
the University of Colorado Health Sciences Center, Denver (M.R.B., W.T.A.), University of Utah Health Sciences Center (E.M.G.), University of North Carolina at Chapel Hill (K.F.A.), Stanford University Hospital, Palo Alto, Calif (M.B.F.), Oregon Health Sciences Center, Portland (R.E.H.), University of Minnesota, Minneapolis (S.H.K.), University of California at Los Angeles Medical Center (K.A.N.), Sharp-Reese Stealy Medical Clinic, San Diego, Calif (H.I.), Nebraska Heart Institute, Lincoln (S.K.), and SmithKline Beecham Pharmaceuticals, King of Prussia, Pa (S.Y., N.S.).
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionAppendix References |
|---|
Background We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" ß-blocking agent with vasodilator properties, in chronic heart failure.
Methods and Results Three hundred forty-five subjects with mild to moderate, stable chronic heart failure were randomized to receive treatment with placebo, 6.25 mg BID carvedilol (low-dose group), 12.5 mg BID carvedilol (medium-dose group), or 25 mg BID carvedilol (high-dose group). After a 2- to 4-week up-titration period, subjects remained on study medication for a period of 6 months. The primary efficacy parameter was submaximal exercise measured by two different techniques, the 6-minute corridor walk test and the 9-minute self-powered treadmill test. Carvedilol had no detectable effect on submaximal exercise as measured by either technique. However, carvedilol was associated with dose-related improvements in LV function (by 5, 6, and 8 ejection fraction [EF] units in the low-, medium-, and high-dose carvedilol groups, respectively, compared with 2 EF units with placebo, P<.001 for linear dose response) and survival (respective crude mortality rates of 6.0%, 6.7%, and 1.1% with increasing doses of carvedilol compared with 15.5% in the placebo group, P<.001). When the three carvedilol groups were combined, the all-cause actuarial mortality risk was lowered by 73% in carvedilol-treated subjects (P<.001). Carvedilol also lowered the hospitalization rate (by 58% to 64%, P=.01) and was generally well tolerated.
Conclusions In subjects with mild to moderate heart failure from systolic dysfunction, carvedilol produced dose-related improvements in LV function and dose-related reductions in mortality and hospitalization rate.
Key Words: carvedilol • heart failure • exercise • vasodilation • receptors, adrenergic, beta
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix References |
|---|
In an attempt to stabilize compromised pump performance, the failing human heart is subjected to increased adrenergic stimulation.1 2 3 4 5 Although this compensatory mechanism may initially support and maintain cardiac output, model systems6 7 and human studies8 9 10 11 12 provide considerable evidence that continuous adrenergic stimulation may be harmful. Perhaps the most compelling evidence that chronic adrenergic stimulation is harmful to the failing heart derives from experience with ß-adrenergic blocking agents, which consistently improve LV function in subjects with chronic heart failure13 14 15 16 17 18 19 20 21 22 by reversing intrinsic systolic dysfunction15 16 20 via a time-dependent "biological" effect on the myocardium.23
Carvedilol is a "third-generation"24 ß-blocking agent that at therapeutic target doses blocks all three adrenergic receptors that mediate a positive inotropic response in human cardiac myocytes, with a rank order of potency of ß1>
1>ß2.25 Because of its -blocking properties,26 27 carvedilol is a moderate vasodilator on acute administration,21 28 but with long-term treatment the vasodilator activity is no longer prominent.17 However, the vasodilator action of the compound contributes to its relatively good initial tolerability, because, in contrast to nonvasodilator ß-blockers,29 30 acute administration of carvedilol does not typically result in profound myocardial depression and clinically important reductions in cardiac output.21 28
One important aspect of investigating drug action is to define both efficacy and adverse event dose-response characteristics to calculate a therapeutic index and predict a risk:benefit ratio for individual patients. Although previous single-center smaller trials conducted with a single target dose of 25 to 50 mg BID have indicated that carvedilol improves LV function and may improve heart failure symptoms and submaximal exercise,17 18 21 the influence of dose on these and other important parameters in longer-term follow-up is unknown. For these reasons, we undertook an evaluation of the dose-response characteristics of carvedilol over a 6-month period of maintenance treatment in a design that included evaluation of functional capacity (submaximal exercise), LV function, heart failure symptoms, heart failure morbidity, and survival.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix References |
|---|
Protocol Description
The MOCHA trial was a 6-month, double-blind, placebo-controlled, multicenter dose-response evaluation of this third-generation ß-blocking agent in subjects with stable, symptomatic, chronic heart failure. Four treatment groups were evaluated: placebo, low-dose carvedilol (6.25 mg BID), medium-dose carvedilol (12.5 mg BID), and high-dose carvedilol (25 mg BID).
The primary objective of this trial was to compare the efficacy of three increasing doses of carvedilol with that of placebo for improvement in submaximal exercise. Two submaximal exercise tests were used: the 6-minute walk test31 and the 9-minute self-powered treadmill test.32 The secondary objectives of this trial were to assess changes in QOL with the Minnesota Living With Heart Failure questionnaire,33 changes in NYHA functional class, changes in EF, need for hospitalization due to heart failure and other cardiovascular causes, and changes in signs and symptoms of heart failure. The safety assessment included an evaluation of the occurrence of adverse clinical experiences, changes in laboratory values, deaths, and ECG values in the four treatment arms.
Patients initially underwent a 3-week screening phase, during which time eligibility for the trial was determined, including a baseline radionuclide LVEF. Qualified patients signed informed written consent, followed by performance of additional baseline measurements and then institution of a 2-week challenge phase of open-label carvedilol. The carvedilol challenge consisted of an initial dose of 6.25 mg BID, which could be reduced to 3.125 mg BID if the patient developed symptoms related to hypotension or worsening heart failure. In patients reduced to 3.125 mg BID, the challenge dose was increased to 6.25 mg BID in the second week, and successful placement on this dose was required to establish tolerability. Patients tolerating challenge were then randomized to one of the four treatment groups. Study medication was increased on a weekly basis in the 12.5-mg BID and 25-mg BID carvedilol groups, such that at the end of 2 weeks of up-titration all patients would have reached their target or maximally tolerated dose. All patients were up-titrated in a fashion that maintained the double-blind feature. Patients having difficulty with up-titration could return to the previous level and had 4 weeks to reach the target dose. After up-titration, a 6-month maintenance period ensued, during which time patients received placebo or one of the three different doses of carvedilol and were followed up at frequent intervals by the investigators and study nurses. After 6 months of maintenance treatment, efficacy tests performed at baseline were repeated. In addition, submaximal exercise tests and QOL measurements were performed at the end of 2 and 4 months of maintenance treatment, and NYHA functional class and global assessments were determined on a monthly basis during maintenance treatment.
Entry criteria for this study included male or female patients between 18 and 85 years of age who had an EF 
35% and symptomatic heart failure from ischemic or nonischemic dilated cardiomyopathy. Symptoms had to be present for at least 3 months, the 6-minute walk test had to be between 150 and 425 m (revised upward to 150 to 450 m by protocol amendment 6 months into the study), and stability was defined as no change in NYHA class or absence of hospitalization for heart failure during the 1 month before baseline testing. Patients had to be on stable doses of diuretics for 2 weeks before baseline testing and a stable dose of ACE inhibitor for at least 1 month before baseline testing. Patients who were intolerant of ACE inhibitors were allowed in the study, but they could not be rechallenged with an ACE inhibitor during the course of the trial. Digoxin use was optional, but if patients were taking digoxin, they had to have been started at least 2 months before baseline testing and to have been on a stable dose for at least 1 month. The use of hydralazine and nitrates was also optional, but if patients were on these medications they had to have been started at least 2 months before baseline testing and to have been on a stable dose for at least 1 month. Additional entry criteria included a resting heart rate in the sitting position of 
68 bpm.
Exclusion criteria included the presence of uncorrected valvular disease, hypertrophic cardiomyopathy, or postpartum cardiomyopathy. Additional exclusion criteria included documented uncontrolled symptomatic or sustained ventricular tachycardia. Acute myocardial infarction could not have occurred within 3 months before screening, and a percutaneous transluminal coronary angioplasty, coronary artery bypass graft surgery, or heart transplant could not be planned or be likely within the 6 months after screening. Other exclusions included the presence of sick sinus syndrome, second- or third-degree heart block not treated with a pacemaker, symptomatic peripheral vascular disease limiting exercise testing, a sitting systolic blood pressure of <85 mm Hg or >160 mm Hg, a cerebrovascular accident within the previous 3 months, cor pulmonale, obstructive pulmonary disease requiring oral bronchodilator or steroid therapy, serum creatinine >2.5 mg/dL, serum SGOT or SGPT >3 times the upper limits of normal, a chronic biliary disorder, limitation of exercise other than that due to heart failure, a systemic or terminal disease that would limit physical function or survival during the trial, an untreated endocrine disorder such as hyperthyroidism, brittle insulin-dependent diabetes requiring frequent hospitalizations, an alcohol intake of >100 g/d, unwillingness to cooperate or give written informed consent, pregnant or lactating women, platelet count <100 000 mm3 or white blood cell count <3000 mm3, use of an investigational drug within 30 days of entry into the challenge phase, and a history of drug sensitivity or adverse reactions to - or ß-blockers. The following medications were excluded for concomitant use within 2 weeks of baseline testing: monamine oxidase inhibitors, calcium channel blockers, flosequinan, - or ß-blockers, disopyramide, flecainide, encainide, moricizine, propafenone, or sotalol. Amiodarone could not have been used within 3 months of baseline testing.
The 6-minute corridor walk test was conducted as previously described by Guyatt et al.31 A 9-minute self-activated treadmill test32 was performed in a standardized fashion with a Tunturi Jogger II mechanical treadmill equipped with odometers that were standardized in all centers. Only subjects whose baseline or screening exercise tests were limited by dyspnea or fatigue were continued in the study. When exercise tests were performed on the same day, the 6-minute walk test was performed first, and at least a 1-hour rest period was allowed before the second test. Subjects underwent at least four baseline exercise tests before initial drug challenge: two during the screening phase to familiarize subjects with the tests and at least two during baseline testing. Results of the fourth 6-minute walk test were used as the baseline value provided that the distance was within ±10% of the previous test. If this was not the case, the subject returned for an additional test and was discontinued from the study if the distance was not within ±10% of the previous test. Whenever a 6-minute walk test was performed, a 9-minute treadmill test was also obtained.
LVEF was measured by radionuclide ventriculography. Hospitalizations due to heart failure or other cardiovascular causes were reported prospectively by the investigators, and mortality was classified by the US Carvedilol Heart Failure Trials Program Steering Committee according to procedures used in the PROMISE11 and SAVE34 trials. A data and safety monitoring board prospectively monitored the serious adverse events, including deaths, in this and the three other US carvedilol trials that composed the trial program.
Statistical Analysis
On the basis of a review of the literature and preliminary data available from pilot studies,17 18 it was projected that a sample size of 300 patients (75 per treatment group) would provide 90% power at the P=.05 level of significance to detect a dose-response effect for both the 6-minute corridor and 9-minute self-powered treadmill walk tests. The effect sizes used for the power calculations for the 6-minute corridor walk test were 7 m,14 m, 28 m, and 56 m for the placebo group and the 6.25-mg-BID, 12.5-mg-BID, and 25-mg-BID carvedilol groups, respectively. All analyses were by intent to treat; patients who did not tolerate their target dose and were maintained at a lower dose were analyzed with the treatment group to which they were originally randomized. For submaximal exercise tests, heart failure global assessments, QOL measurements, and estimates of NYHA functional class, the end-point value used was the last available measurement. Per protocol specification, the secondary end point of hospitalizations for heart failure or other cardiovascular reasons was tabulated during the maintenance period for patients completing at least 2 months of maintenance. The analysis of deaths was inclusive of the entire up-titration and maintenance periods.
For the primary efficacy evaluations (change from baseline in distance covered for each of the two walk tests), both multivariate and univariate ANOVA procedures that included the effects of study center, treatment group, and the interaction between them were used. The effectiveness of carvedilol was assessed with a two-tailed test for linear trend, and if it was significant, pairwise comparisons with placebo were performed. In addition, 95% CIs on the difference between each carvedilol group and the placebo mean change were estimated. Supplemental analyses of the primary efficacy variables using two-way ANOVA on rank-transformed data were carried out to determine the effects of early termination or withdrawal from the study. The change from baseline for all continuous secondary and safety variables was analyzed by use of the same model as for the primary efficacy analysis; categorical variables were analyzed by contingency table analyses using the Cochran-Mantel-Haenszel procedure when necessary. Once these predetermined assessments were completed, patients were stratified for subgroup analyses by baseline variables that could have influenced outcomes. ANOVA procedures were used to evaluate the significance of drug-stratification variable interactions. All-cause mortality was tested for linear trend in two ways: (1) by examination of the linear component of the total 
2 (using the Mantel-Haenszel option) to assess crude rates and (2) by use of a Cox proportional-hazards regression model with treatment as covariant to assess the linear relationship among the four treatment groups. Other categorical variables were analyzed as per crude mortality rates by contingency table analysis. In these categorical analyses, when the linear trend test was significant (P<.05), the significance of individual carvedilol groups compared with placebo was determined by 2x2 contingency table analysis, without adjustment for multiple groups. Finally, additional analyses of mortality and other important categorical variables were performed by combining all the carvedilol groups into one active treatment group and comparing the results with those of the placebo groups. For mortality, Kaplan-Meier curves were constructed by use of a Cox regression model, and crude mortality rates and other categorical variables were compared by contingency table analysis as described above.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix References |
|---|
Subject Demographics and Baseline Cardiac and Exercise Function
As can be observed in Table 1
, there were no differences in subject descriptors among the four treatment groups. The majority of subjects were Caucasian men 
60 years old who were evenly divided between NYHA class II and class III heart failure, who had moderate to severe LV dysfunction with a mean EF of 23%, and who had moderate impairment of submaximal exercise, with baseline 6-minute walk tests of 360 m. Table 2 shows the percentages of subjects on digoxin, diuretics, and ACE inhibitors on entry into and during the maintenance period of the trial, because background treatment could not be altered by adding or dropping these medications.
|
|
Results of Open-Label Challenge
Fig 1 gives the carvedilol challenge data. Three hundred seventy-six subjects signed informed consent forms and received a 6.25-mg-BIDx2-week challenge of open-label carvedilol. As shown in Figs 1 and 2, 92% of subjects tolerated this challenge and were randomized to one of the four groups. As shown in Fig 2, in the majority of subjects who did not tolerate challenge, this was because of adverse events, primarily symptoms related to orthostatic hypotension or myocardial depression. One subject died during the 2- to 4-week challenge period.
|
|
Target Doses Achieved, Heart Rate, and Blood Pressure Effects
Table 3 gives the maintenance doses of study medication achieved in the four groups. As can be seen, the maintenance doses in the three carvedilol groups were similar to the target doses. Heart rate data obtained from the ventricular rate of ECGs taken at baseline and at 2, 4, and 6 months of maintenance treatment are also given in Table 3. There is a reduction in heart rate at all three doses of carvedilol that is minimally dose-related. As shown in Table 3, systolic and diastolic blood pressures taken in the sitting position were not affected by chronic carvedilol treatment.
|
Median Follow-up, Adverse Events, and Discontinuation From Study Medication
This trial consisted of an initial up-titration period of 2 to 4 weeks, followed by 6 months on maintenance treatment. The intent-to-treat median values for exposure to study medication were 190, 194, 196, and 196 days on the placebo, 6.25-mg-BID, 12.5-mg-BID, and 25-mg-BID groups, respectively. A list of adverse events encountered on study medication is given in Table 4. As can be seen, by linear trend test the only adverse events more prevalent in carvedilol-treated subjects were dizziness and bradycardia. As shown in Table 5, however, relatively few carvedilol-treated subjects were withdrawn because of adverse effects—in fact, a lower percentage than in the placebo group. It can also be observed in Table 5 that the overall discontinuation from the study rate was lower in the carvedilol groups than in the placebo group.
|
|
Submaximal Exercise
Fig 3 gives the 6-minute walk results, one of two components of the primary end point. Fig 4 gives the results of the second component of the primary end point, the 9-minute self-activated treadmill test. As can be seen in Figs 3 and 4, compared with the placebo group, carvedilol had no effect on either component.
|
|
LV Function
Fig 5 gives the results on LV function as assessed by radionuclide ventriculography expressed as the change from baseline in EF units (%) in the four groups. Carvedilol treatment resulted in a dose-related improvement in LVEF, with each group being statistically significantly different from placebo and the dose response assessed by the linear-trend test being highly statistically significant (P<.01). The effect of carvedilol was apparent for both ischemic and nonischemic cardiomyopathies (Fig 6). As Fig 6 shows, there was a tendency for the improvement in LV function to be more dose-related in the nonischemic group. However, there was no statistically significant difference between the dose-response relations by the linear-trend test (P=.068).
|
) from baseline values.
|
Hospitalizations
Fig 7 and Table 6 give the cardiovascular hospitalization rate per subject data, obtained as per protocol during the 2- to 6-month maintenance phase of the trial. As can be seen in Fig 7, carvedilol treatment was associated with a reduction in cardiovascular hospitalization rate that was statistically significant in all individual groups and for linear trend. As can be observed in Table 6, the reduction in hospitalization rate in the carvedilol groups was not at the expense of length of hospital stay.
|
|
Although it was not a protocol-specified end point, we also analyzed total hospitalizations from time of randomization. As a percentage of the number of patients randomized, the results were 23.8%, 13.2%, 18.0%, and 13.5% in the placebo and three increasing carvedilol doses, respectively (P=.16 by linear trend). The mean numbers of hospitalizations per patient were 0.37, 0.16, 0.21, and 0.18, respectively (P=.07 by linear trend). The mean number of hospital days per patient was reduced by carvedilol (3.1, 1.1, 1.5, and 1.3, respectively, P=.01). In all hospitalization categories, if the carvedilol groups were combined, there was a significant reduction (P<.05) in favor of carvedilol treatment.
QOL and Global Assessment Measurements
Table 7 presents the results of the Minnesota Living With Heart Failure Questionnaire, indicating that there are no significant differences among the four groups in this index expressed as the total score incorporating both physical and emotional dimensions.33 There were also no significant changes in the individual components of the Minnesota Questionnaire (physical dimension, respective mean changes from baseline in the placebo and low-, medium-, and high-dose carvedilol groups of -3.1, -3.7, -3.2, and -2.0 [P=.360] and emotional dimension, -1.4, -1.5, -1.3, and -0.5 [P=.25]). Results of patient and physician global assessments are given in Table 8, and for both types of assessment groups, carvedilol treatment was associated with a trend toward significant improvement. NYHA functional class ranking was also unaffected by carvedilol (P=.64 for linear trend in improvement, data not shown).
|
|
Survival
Fig 8 gives the crude mortality rate as a percentage of randomized subjects in the four treatment groups. The placebo-treated group had 13 deaths, for a 15.5% crude mortality over the 6 months of the study. As can be observed in Fig 8, there was a dose-related, statistically significant reduction in mortality in the carvedilol-treated groups, with respective mortality rates of 6.0% (log-rank analysis: relative risk, 0.356 with 95% CI of 0.127 to 0.998, P<.05), 6.7% (relative risk, 0.416 and 95% CI, 0.158 to 1.097, P=.07), and 1.1% (relative risk, 0.067 and 95% CI, 0.009 to 0.512, P<.001) for the carvedilol doses of 6.25 mg BID, 12.5 mg BID, and 25 mg BID, respectively. As shown in Fig 8, the reduction in mortality by carvedilol was highly statistically significant (P<.001) by the linear trend test.
|
Fig 9 gives actuarial survival curves for the three carvedilol groups combined and compared with the placebo-treated group. As can be observed, by log-rank analysis there was a highly statistically significant reduction in mortality (by 73%; relative risk, 0.272 and CI, 0.124 to 0.597, P<.001) in carvedilol-treated subjects. Moreover, the reduction in mortality shown in Fig 9 appeared to occur in both ischemic and nonischemic cardiomyopathies, with respective relative risk reductions in the crude mortality rate of 73% and 63% (Table 9). In addition, carvedilol appeared to favorably affect deaths classified as sudden as well as those due to progressive pump dysfunction, as shown in Table 9.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix References |
|---|
In failing human ventricular myocardium, ß-blocking agents produce effects unique among heart failure medications. Initially, ß-blocking agents depress myocardial function through the pharmacological action of withdrawal of adrenergic support to the myocardium, but after several months of treatment they improve intrinsic myocardial function through a time-dependent and as yet undetermined salutary "biological" effect on failing heart muscle.23 35 The third-generation ß-blocker/vasodilator carvedilol differs from first-generation compounds such as propranolol or timolol in that it produces less initial hemodynamic compromise, since on acute dosing, cardiac output is usually maintained or even slightly increased because of the vasodilator properties of the compound.21 28 Indeed, in phase II studies in moderate or severe heart failure, carvedilol was very well tolerated,17 18 21 in contrast to propranolol.36 Carvedilol differs from second-generation, ß1-selective compounds in that (1) at higher doses it blocks ß2- and
1- as well as ß1-receptors; (2) it reduces cardiac adrenergic activity37 ; and (3) it prevents ß-receptor upregulation and restoration of ß-adrenergic signal transduction,25 37 which typically occurs with metoprolol.29 37 38 The result is that at target pharmacological doses, such as those used in phase II heart failure trials,17 18 21 carvedilol produces a complete and comprehensive antiadrenergic action in the failing human heart. In this trial, carvedilol produced a dose-related improvement in LV function as assessed by radionuclide-determined EF similar to previously reported results with bucindolol.22 The increase in LVEF by the highest dose (25 mg BID) of carvedilol was similar to results in three previously reported phase II trials with carvedilol.17 18 21 The increase in LVEF occurred in both ischemic and nonischemic cardiomyopathies, which is consistent with previous carvedilol data17 18 21 and with previous results with the third-generation nonselective ß-blocker bucindolol.22 In what appeared to be a mirror-image pattern to the improvement in LV function, carvedilol was associated with a dose-related reduction in mortality. Moreover, this reduction in mortality appeared to be present in both ischemic and nonischemic cardiomyopathies and was observed for both sudden and progressive pump dysfunction classifications of death. This differs from results reported for the second-generation compound bisoprolol, which in the CIBIS trial39 did not reduce mortality in the ischemic cardiomyopathy population and did not reduce the incidence of sudden death. Although in MOCHA the number of deaths was small (a total of 25), the dose-relatedness of the apparent survival benefit and the robust significance levels (P<.001 both for linear dose response and for the combined carvedilol groups, relative risk reduction of 73% for the combined carvedilol groups with confidence limits not including 1.0) support the interpretation that the observed mortality-reducing effect was not due to chance. In addition, results in the combined US Carvedilol Heart Failure Trials Program indicate a similar, highly statistically significant reduction in mortality (by 65%) that was consistent across all trials.40 Although the current results on mortality reduction by carvedilol exceed the quantitative estimates from the CIBIS (by 21%)39 and MDC (by 35% for the combined morbidity-mortality end point)19 trials, differences in the degree of antiadrenergic action37 or important ancillary properties such as antioxidant effects41 provide a potential pharmacological basis for the greater efficacy of carvedilol.
The "primary" end point of this study, improvement in submaximal exercise, was not altered by treatment with carvedilol. This is in contrast to results in two phase II trials, in which, compared with placebo, carvedilol either improved the 6-minute walk distance18 or, compared with baseline, improved the duration of sustained submaximal exercise maintained at a fixed percentage of the workload.17 The intent was to measure submaximal exercise by two techniques, in view of the lack of a generally accepted method that can be used to establish efficacy of heart failure treatment. Unfortunately, information available after the completion of the trial indicates that the 9-minute self-powered treadmill test, although quite reproducible, measures predominantly maximal rather than submaximal exercise capacity.42 In the present study, no positive trends in favor of carvedilol were noted in either the 6-minute corridor walk or the 9-minute self-powered treadmill test. However, on the basis of the MOCHA trial data, it can be stated that carvedilol has no adverse effect on submaximal or maximal exercise, which is important for the use of this type of agent in chronic heart failure. The reason that carvedilol did not improve submaximal exercise may relate to a true lack of a treatment effect or to methodological difficulties in measuring submaximal exercise in multicenter trials.
Carvedilol was associated with a reduction in cardiovascular hospitalization rate by 58% to 64%. This important index of morbidity, QOL, and pharmacoeconomics was reduced by all three doses of carvedilol. Although the reduction in hospitalization rate obeyed a dose-response pattern statistically, within the carvedilol-treated groups there was no obvious relationship between increasing dose and decreasing rate. QOL as assessed by the Minnesota instrument33 was not statistically improved by carvedilol at the end of the study. However, there was a trend toward improvement by carvedilol in the global assessment instrument for both the patient and physician assessments. On balance, the lack of a measurable effect on improvement in QOL is similar to what was observed in the bucindolol multicenter trial, in which the same instrument did not detect differences between active drug and placebo after 12 weeks of treatment. As with carvedilol,17 18 bucindolol13 14 had been associated with improved QOL in smaller single-center studies that used different assessment techniques. It is likely that the inconsistency in these results is due to difficulties in measuring QOL, the unique effects of ß-blocker therapy in a heart failure population in which benefit may be variably preceded by drug-related worsening of symptoms and QOL, or an inherent lack of a favorable QOL effect with this type of treatment. However, the latter would seem unlikely in view of the aforementioned previous positive QOL results. The most likely explanation may be the relatively short duration of follow-up. This explanation is supported by QOL data from the MDC trial, in which metoprolol was associated with an improved QOL at 12 or 18 months.
This trial was not designed to evaluate an efficacy effect on mortality, because in the entire Carvedilol US Trials program, deaths were being assessed primarily as a safety end point. In addition, the median follow-up of 6 months was less than is usually associated with mortality trials. However, it should be noted that the number of subjects enrolled in the MOCHA trial was 36% greater and the median follow-up was longer than in CONSENSUS-I,43 a trial that is widely considered to have unambiguously demonstrated a mortality reduction by the ACE inhibitor enalapril. Although the CONSENSUS trial had more end points (a total of 118 deaths), the present trial has the advantage of having demonstrated a highly significant dose-related reduction in mortality that correlated with a progressive reduction in estimated catecholamine ß-receptor occupancy to values that are probably below or close to the pharmacological thresholds of norepinephrine- or epinephrine-mediated responses.44
Finally, the results of this study strongly support the hypothesis23 35 that the improvement in LV function observed for ß-blocking agents is associated with improved survival. Unlike that for positive inotropic agents or vasodilators, improvement in LV function by antiadrenergic treatment is via a time-dependent "biological" improvement in intrinsic systolic function,23 35 resulting in a partial reversal of the underlying abnormalities afflicting the failing human heart. It is perhaps not surprising that such a favorable effect on the intrinsic myocardial function would be associated with an improvement in the natural history of heart failure, but until now the data supporting this concept were only suggestive.19 39 The fact that carvedilol is associated with an apparently greater effect on survival than are second-generation compounds is also not surprising, in view of the more complete antiadrenergic properties of carvedilol25 37 and/or the existence of additional favorable ancillary properties.41
In summary, in this trial carvedilol produced a dose-related reduction in mortality in a chronic heart failure population. In addition, MOCHA is the first individual clinical trial to demonstrate a mortality benefit with ß-blocker treatment in chronic heart failure. Although the number of deaths in the trial was small (n=25), the dose-relatedness of the findings and the relationship to improved LV systolic function suggests that the observations are not due to chance. Further clinical trials will be necessary to confirm and extend these findings as well as to position this treatment into its proper place in the treatment of chronic heart failure.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This study was supported by SmithKline Beecham Pharmaceuticals, Boehringer Mannheim Corp, and NIH grant R01-HL-48013 awarded to Dr Bristow.
|
Footnotes |
|---|
Reprint requests to Michael R. Bristow, MD, PhD, Head, Division of Cardiology, University of Colorado HSC, 4200 E 9th Ave, B139, Denver, CO 80262. E-mail michael.bristow@uchsc.edu.
|
Appendix |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix References |
|---|
The following investigators (and their performance sites) composed the MOCHA Study Group.
L. Kuo, Albuquerque, NM (Lovelace Scientific Resources); R. Karlsburg, Beverly Hills, Calif; K. Adams, Chapel Hill, NC (University of North Carolina); E. Eichhorn, Dallas, Tex (Dallas Veterans Administration Medical Center); C.W. Yancy, Dallas, Tex (University of Texas Southwestern Medical Center); M. Bristow, W. Abraham, Denver, Colo (University of Colorado); J. Young, Houston, Tex (Baylor College of Medicine); S.E. El Hafi, Houston, Tex; G. Schroth, Houston, Tex (University of Texas Medical School); J. O'Connell, Jackson, Miss (University of Mississippi Medical Center); A. Miller, Jacksonville, Fla (University of Florida); J.A. Bowers, Las Vegas, Nev (Heart Institute of Nevada); S. Krueger, Lincoln, Neb (Nebraska Heart Institute); V. DeQuattro, Los Angeles, Calif (University of Southern California School of Medicine); P.S. Rahko, Madison, Wis (University of Wisconsin); K.B. Ramanathan, Memphis, Tenn (University of Tennessee, Memphis); E. deMarchena, Miami, Fla (University of Miami); S. Kubo, J. Cohn, Minneapolis, Minn (University of Minnesota Medical School); U. Thadani, Oklahoma City, Okla (University of Oklahoma Health Sciences Center); R.P. Sorkin, Park Ridge, Ill (Lutheran General Hospital); J.V. Felicetta, Phoenix, Ariz (Carl T. Hayden VA Medical Center); R. Hershberger, Portland, Ore (Oregon Health Sciences); L.J. Olson, Rochester, Minn (Mayo Medical School); E.M. Gilbert, Salt Lake City, Utah (University of Utah); L. Yellen, San Diego, Calif (Cardiology Associates Medical Group of East San Diego, Inc); H. Ingersoll, San Diego, Calif (Sharp Rees-Stealy Medical Group Center); S. Woodley, San Francisco, Calif (California Pacific Medical Center); B. Massie, San Francisco, Calif (Veterans Administration Medical Center); M. Fowler, Stanford, Calif (Stanford University Cardiovascular Medicine); L.W. Miller, S.H. Jennison, St Louis, Mo (St Louis University); A.J. Lonigro, H. Stratmann, St Louis, Mo (St Louis University Medical Center); K.A. Narahara, Torrance, Calif (Harbor-UCLA Medical Center); S. Butman, Tucson, Ariz (University Medical Center); F. Kahl, Winston-Salem, NC (Bowman-Gray School of Medicine).
US Multicenter Carvedilol Trials Program Steering Committee: M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, M. Packer. Data and Safety Monitoring Board: A.M. Katz (chair), T. Bashore, C.E. Davis, P. Kowey. Biostatistics: J. Hosking (University of North Carolina), S.T. Young (SmithKline Beecham Pharmaceuticals). Study Operations/Monitoring: N.H. Shusterman, M.A. Lukas, A. Flagg, T. Holcslaw, L.G. Parchman (SmithKline Beecham Pharmaceuticals).
Received June 10, 1996; revision received September 3, 1996; accepted September 9, 1996.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionAppendix References |
|---|
1. Gaffney TE, Braunwald E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 1963;34:320-324.[Medline] [Order article via Infotrieve]
2. Bristow MR, Ginsburg R, Minobe WA, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and ß-adrenergic receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.[Abstract]
3. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chatterjee K. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol. 1984;54:783-786.[Medline] [Order article via Infotrieve]
4.
Hasking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
5. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. ß-Adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985;17:41-52.
6.
Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
7. Reichenbach DD, Bendett ED. Catecholamines and cardiomyopathy: the pathogenesis and potential importance of myofibrillar degeneration. Hum Pathol. 1970;1:125-150.
8.
White M, Wiechmann RJ, Roden RL, Hagan MB, Wollmering MM, Port JD, Hammond E, Abraham WT, Wolfel EE, Lindenfeld J, Fullerton D, Bristow MR. Cardiac ß-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury: evidence for catecholamine-mediated myocardial damage. Circulation. 1995;92:2183-2189.
9. Imperato-McGinley F, Gautier T, Ehlers K, Zullo MA, Goldstein DS, Vaughan ED Jr. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N Engl J Med. 1987;316:793-797.[Medline] [Order article via Infotrieve]
10. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.[Abstract]
11. Packer M, Carver JR, Rodenheffer RJ, Ivanhoe RJ, DiBlanco R, Zeldis SM, for the PROMISE Study Group. Effect of oral milrinone on mortality in severe chronic heart failure: the Prospective Randomized Milrinone Survival Evaluation (PROMISE). N Engl J Med. 1991;325:1468-1475.[Abstract]
12. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6.[Medline] [Order article via Infotrieve]
13. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealy PC, Larrabee P, Bristow MR. Long-term ß-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-229.[Medline] [Order article via Infotrieve]
14. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 1990;66:603-607.[Medline] [Order article via Infotrieve]
15.
Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, Willard JE, Grayburn PA. Effect of ß-adrenergic blockade on myocardial function and energetics in congestive heart failure. Circulation. 1990;82:473-483.
16. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 1993;21:1094-1100.
17. Olsen SL, Gilbert EM, Renlund DG, Mealey PC, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
18.
Krum H, Sakner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499-1506.
19. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Johnson M, Silver MA, Gilbert EM, Hjalmarson Å. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.[Medline] [Order article via Infotrieve]
20. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
21. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
22.
Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker M, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators. Dose-response of chronic ß-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
23. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biologic effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995;16(suppl F):20-31.
24. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C.[Medline] [Order article via Infotrieve]
25. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe WA, Tremmel RD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996;17:8-16.
26. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, Muller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992;19(suppl 1):S68-S80.
27. Bristow MR, Larrabee P, Muller-Beckmann B, Minobe W, Roden R, Skerl RL, Klein J, Handwerger D. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest. 1992;70:S105-S113.
28. Di Lenarda A, Gilbert EM, Olsen SL, Mealey PC, Bristow MR. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1991;17:142A. Abstract.
29.
Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson Å. Long-term ß-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989;80:551-563.
30.
Haber HL, Simek CL, Gimple LW, Bergin JD, Subbiah K, Jayaweera AR, Powers ER, Feldman MD. Why do patients with congestive heart failure tolerate the initiation of ß-blocker therapy? Circulation. 1993;88:1610-1619.
31. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919-923.[Abstract]
32.
Sparrow J, Parameshwar J, Poole-Wilson PA. Assessment of functional capacity in chronic heart failure: time-limited exercise on a self-powered treadmill. Br Heart J. 1996;71:391-394.
33. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J. 1992;124:1017-1025.[Medline] [Order article via Infotrieve]
34. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Werthheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.[Abstract]
35.
Eichhorn EE, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation. 1996;94:2285-2296.
36. Stephen SA. Unwanted effects of propranolol. Am J Cardiol. 1966;18:463-472.[Medline] [Order article via Infotrieve]
37. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, LV functional, and anti-adrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation. In press.
38.
Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased ß-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483-490.
39.
CIBIS Investigators. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation.. 1994;90:1765-1773.
40.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
41.
Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feurstein R, Gu J-L, Lsko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
42. Yamani MH, Wells L, Massie BM. Relation of the nine-minute self-powered treadmill test to maximal exercise capacity and skeletal muscle function in patients with congestive heart failure. Am J Cardiol. 1995;76:788-792.[Medline] [Order article via Infotrieve]
43. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.[Abstract]
44.
Bristow MR, Abraham WT, Gilbert EM, Yoshikowa T, Port JD. Relationships between carvedilol stereoisomer plasma concentrations and ß-receptor occupancies in subjects with chronic heart failure in the MOCHA Trial. Eur Heart J. 1996;17:135. Abstract.
This article has been cited by other articles:
 |
|
 |
|
  M. K. Duda, K. M. O'Shea, and W. C. Stanley {omega}-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential Cardiovasc Res, October 1, 2009; 84(1): 33 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Klapholz {beta}-Blocker Use for the Stages of Heart Failure Mayo Clin. Proc., August 1, 2009; 84(8): 718 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. McAlister, N. Wiebe, J. A. Ezekowitz, A. A. Leung, and P. W. Armstrong Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure Ann Intern Med, June 2, 2009; 150(11): 784 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghio, N. Freemantle, L. Scelsi, A. Serio, G. Magrini, M. Pasotti, A. Shankar, J. G.F. Cleland, and L. Tavazzi Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial Eur J Heart Fail, May 1, 2009; 11(5): 480 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
 |
|
 2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
|
|
A. Mebazaa, M. S. Nieminen, G. S. Filippatos, J. G. Cleland, J. E. Salon, R. Thakkar, R. J. Padley, B. Huang, and A. Cohen-Solal Levosimendan vs. dobutamine: outcomes for acute heart failure patients on {beta}-blockers in SURVIVE Eur J Heart Fail, March 1, 2009; 11(3): 304 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Willenheimer The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial Eur. Heart J. Suppl., March 1, 2009; 11(suppl_A): A15 - A20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Parissis, M. Nikolaou, D. Farmakis, I. A. Paraskevaidis, V. Bistola, K. Venetsanou, D. Katsaras, G. Filippatos, and D. T. Kremastinos Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure Eur J Heart Fail, February 1, 2009; 11(2): 163 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Naya, T. Tsukamoto, K. Morita, C. Katoh, K. Nishijima, H. Komatsu, S. Yamada, Y. Kuge, N. Tamaki, and H. Tsutsui Myocardial {beta}-Adrenergic Receptor Density Assessed by 11C-CGP12177 PET Predicts Improvement of Cardiac Function After Carvedilol Treatment in Patients with Idiopathic Dilated Cardiomyopathy J. Nucl. Med., February 1, 2009; 50(2): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Kwon, C. M. Halley, T. P. Carrigan, V. Zysek, Z. B. Popovic, R. Setser, P. Schoenhagen, R. C. Starling, S. D. Flamm, and M. Y. Desai Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. J. Am. Coll. Cardiol. Img., January 1, 2009; 2(1): 34 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. R. B. M. van Gestel, S. E. Hoeks, D. D. Sin, G. M. J. M. Welten, O. Schouten, H. J. Witteveen, C. Simsek, H. Stam, F. W. Mertens, J. J. Bax, et al. Impact of Cardioselective {beta}-Blockers on Mortality in Patients with Chronic Obstructive Pulmonary Disease and Atherosclerosis Am. J. Respir. Crit. Care Med., October 1, 2008; 178(7): 695 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishio, Y. Sakata, T. Mano, T. Ohtani, Y. Takeda, T. Miwa, M. Hori, T. Masuyama, T. Kondo, and K. Yamamoto Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats Eur J Heart Fail, May 1, 2008; 10(5): 446 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Moertl, A. Hammer, M. Huelsmann, R. Pacher, and R. Berger Prognostic value of sequential measurements of amino-terminal prohormone of B-type natriuretic peptide in ambulatory heart failure patients Eur J Heart Fail, April 1, 2008; 10(4): 404 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, V. De Arcangelis, X. Gao, B. Ramani, Y.-s. Jung, and Y. Xiang Norepinephrine- and Epinephrine-induced Distinct 2-Adrenoceptor Signaling Is Dictated by GRK2 Phosphorylation in Cardiomyocytes J. Biol. Chem., January 25, 2008; 283(4): 1799 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Muthumala, F. Drenos, P. M. Elliott, and S. E. Humphries Role of {beta} adrenergic receptor polymorphisms in heart failure: Systematic review and meta-analysis Eur J Heart Fail, January 1, 2008; 10(1): 3 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Albert Switching to Once-Daily Evidence-Based -Blockers in Patients With Systolic Heart Failure or Left Ventricular Dysfunction After Myocardial Infarction Crit. Care Nurse, December 1, 2007; 27(6): 62 - 72. [Full Text] [PDF]
|
|
|
|
|
|
C. Leclercq, G. B. Bleeker, C. Linde, E. Donal, J. J. Bax, M. J. Schalij, and C. Daubert Cardiac resynchronization therapy: clinical results and evolution of candidate selection Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I94 - I106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Shaddy, M. M. Boucek, D. T. Hsu, R. J. Boucek, C. E. Canter, L. Mahony, R. D. Ross, E. Pahl, E. D. Blume, D. A. Dodd, et al. Carvedilol for Children and Adolescents With Heart Failure: A Randomized Controlled Trial JAMA, September 12, 2007; 298(10): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chen, R. Chang, B. Umakanthan, L. N. Stoletniy, and J. T. Heywood Improvement of Cardiac Function Persists Long Term With Medical Therapy for Left Ventricular Systolic Dysfunction Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 220 - 226. [Abstract] [PDF]
|
|
|
|
|
|
D. Dobre, D. J. van Veldhuisen, M. J.L. deJongste, and F. M. Haaijer-Ruskamp Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival Eur J Heart Fail, September 1, 2007; 9(9): 962 - 963. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fenton and M. Burch Understanding chronic heart failure Arch. Dis. Child., September 1, 2007; 92(9): 812 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Hypertension, August 1, 2007; 50(2): e28 - e55. [Full Text] [PDF]
|
|
|
|
|
|
C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation, May 29, 2007; 115(21): 2761 - 2788. [Full Text] [PDF]
|
|
|
|
|
|
R. Berger, D. Moertl, M. Huelsmann, A. Bojic, R. Ahmadi, I. Heissenberger, and R. Pacher Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure Eur J Heart Fail, February 1, 2007; 9(2): 202 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Abdulla, L. Kober, E. Christensen, and C. Torp-Pedersen Effect of beta-blocker therapy on functional status in patients with heart failure -- A meta-analysis Eur J Heart Fail, August 1, 2006; 8(5): 522 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Butler, J. B. Young, W. T. Abraham, R. C. Bourge, K. F. Adams Jr, R. Clare, C. O'Connor, and for the ESCAPE Investigators Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2462 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Feldman The Timing for Transplantation: Superior Genetics or Social Prejudice? J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2243 - 2244. [Full Text] [PDF]
|
|
|
|
|
|
K. S. Chong, R. S. Gardner, J. J. Morton, E. A. Ashley, and T. A. McDonagh Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure Eur J Heart Fail, June 1, 2006; 8(4): 355 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lainscak and I. Keber Patients' knowledge and beta blocker treatment improve prognosis of patients from a heart failure clinic Eur J Heart Fail, March 1, 2006; 8(2): 187 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shigeyama, Y. Yasumura, A. Sakamoto, Y. Ishida, T. Fukutomi, M. Itoh, K. Miyatake, and M. Kitakaze Increased gene expression of collagen Types I and III is inhibited by {beta}-receptor blockade in patients with dilated cardiomyopathy Eur. Heart J., December 2, 2005; 26(24): 2698 - 2705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Castro, J. L. Vukasovic, M. Chiong, G. Diaz-Araya, H. Alcaino, M. Copaja, R. Valenzuela, D. Greig, O. Perez, R. Corbalan, et al. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure Eur J Heart Fail, October 1, 2005; 7(6): 1033 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Sun, S.-J. Hu, L.-H. Wang, Y. Hu, and J.-Y. Zhou Effect of {beta}-Blockers on Cardiac Function and Calcium Handling Protein in Postinfarction Heart Failure Rats Chest, September 1, 2005; 128(3): 1812 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mahrholdt, A. Wagner, R. M. Judd, U. Sechtem, and R. J. Kim Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies Eur. Heart J., August 1, 2005; 26(15): 1461 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K.A. Witte, S. Thackray, N. P. Nikitin, J. G.F. Cleland, and A. L. Clark The effects of long-term {beta}-blockade on the ventilatory responses to exercise in chronic heart failure Eur J Heart Fail, June 1, 2005; 7(4): 612 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Edes, Z. Gasior, and K. Wita Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study Eur J Heart Fail, June 1, 2005; 7(4): 631 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O'Meara, E. Lewis, C. Granger, M. E. Dunlap, R. S. McKelvie, J. L. Probstfield, J. B. Young, E. L. Michelson, J. Ostergren, J. Carlsson, et al. Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme Eur J Heart Fail, June 1, 2005; 7(4): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Mann and M. R. Bristow Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond Circulation, May 31, 2005; 111(21): 2837 - 2849. [Full Text] [PDF]
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G.F. Cleland Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review Eur. Heart J., April 2, 2005; 26(8): 778 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-M. Yu, Q. Zhang, J. W.-H. Fung, H. C.-K. Chan, Y.-S. Chan, G. W.-K. Yip, S.-L. Kong, H. Lin, Y. Zhang, and J. E. Sanderson A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging J. Am. Coll. Cardiol., March 1, 2005; 45(5): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sliwa, G. R. Norton, N. Kone, G. Candy, J. Kachope, A. J. Woodiwiss, C. Libhaber, P. Sareli, and R. Essop Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1825 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-a. Koshimizu, G. Tsujimoto, A. Hirasawa, Y. Kitagawa, and A. Tanoue Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human {alpha}1D- and {alpha}1B-adrenergic receptors Cardiovasc Res, September 1, 2004; 63(4): 662 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Sirak, S. Jelic, and T. H. Le Jemtel Therapeutic update: Non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure J. Am. Coll. Cardiol., August 4, 2004; 44(3): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Task Force Members, J. Lopez-Sendo, K. Swedberg, J. McMurray, J. Tamargo, A. P. Maggioni, H. Dargie, M. Tendera, F. Waagstein, J. Kjekshus, et al. Expert consensus document on {beta}-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology Eur. Heart J., August 1, 2004; 25(15): 1341 - 1362. [Full Text] [PDF]
|
|
|
|
|
|
C. Ward The quality of life in heart failure Just talking about it will not make it better Eur J Heart Fail, August 1, 2004; 6(5): 535 - 537. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chatterjee The Fear of {beta}-Blocker Therapy in Heart Failure: Time to Forget Arch Intern Med, July 12, 2004; 164(13): 1370 - 1371. [Full Text] [PDF]
|
|
|
|
|
|
D. T. Ko, P. R. Hebert, C. S. Coffey, J. P. Curtis, J. M. Foody, A. Sedrakyan, and H. M. Krumholz Adverse Effects of {beta}-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials Arch Intern Med, July 12, 2004; 164(13): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Shah, M K Davies, D Cartwright, and P Nightingale Management of chronic heart failure in the community: role of a hospital based open access heart failure service Heart, July 1, 2004; 90(7): 755 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N G Bellenger, K Rajappan, S L Rahman, A Lahiri, U Raval, J Webster, G D Murray, A J S Coats, J G F Cleland, and D J Pennell Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study Heart, July 1, 2004; 90(7): 760 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. C. Hoppe Beta-blocker induced bradycardia--should we pace? Eur J Heart Fail, June 1, 2004; 6(4): 449 - 451. [Full Text] [PDF]
|
|
|
|
|
|
M. A Movsesian Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy Cardiovasc Res, June 1, 2004; 62(3): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Booth, E. E. Ward, K. C. Colgan, B. L. Funk, H. El-Moalem, M. P. Smith, C. Milano, P. K. Smith, M. F. Newman, and D. A. Schwinn Metoprolol and Coronary Artery Bypass Grafting Surgery: Does Intraoperative Metoprolol Attenuate Acute {beta}-Adrenergic Receptor Desensitization During Cardiac Surgery? Anesth. Analg., May 1, 2004; 98(5): 1224 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tandon, F. A. McAlister, R. T. Tsuyuki, M. Hervas-Malo, R. Dupuit, J. Ezekowitz, B. Cujec, and P. W. Armstrong The Use of {beta}-Blockers in a Tertiary Care Heart Failure Clinic: Dosing, Tolerance, and Outcomes Arch Intern Med, April 12, 2004; 164(7): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Butler, G. Khadim, K. M. Paul, S. F. Davis, M. W. Kronenberg, D. B. Chomsky, R. N. Pierson III, and J. R. Wilson Selection of patients for heart transplantationin the current era of heart failure therapy J. Am. Coll. Cardiol., March 3, 2004; 43(5): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Penicka, J. Bartunek, B. De Bruyne, M. Vanderheyden, M. Goethals, M. De Zutter, P. Brugada, and P. Geelen Improvement of Left Ventricular Function After Cardiac Resynchronization Therapy Is Predicted by Tissue Doppler Imaging Echocardiography Circulation, March 2, 2004; 109(8): 978 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.A. Mehta, S. McDonagh, P.A. Poole-Wilson, R. Grocott-Mason, and S.W. Dubrey Heart failure in a district general hospital: are target doses of beta-blockers realistic? QJM, March 1, 2004; 97(3): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Krum and D. Hare Correspondence Eur. Heart J., February 1, 2004; 25(3): 277 - 277. [Full Text] [PDF]
|
|
|
|
|
|
P. de Groote, N. Helbecque, N. Lamblin, X. Hermant, P. Amouyel, C. Bauters, and J. Dallongeville Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure Eur J Heart Fail, January 1, 2004; 6(1): 17 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ahmed Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure Eur J Heart Fail, December 1, 2003; 5(6): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zanolla and P. Zardini Selection of endpoints for heart failure clinical trials Eur J Heart Fail, December 1, 2003; 5(6): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R S Gardner, W Martin, R Carter, and T A McDonagh Importance of {beta} blockade in the treatment of advanced heart failure Heart, December 1, 2003; 89(12): 1442 - 1444. [Full Text] [PDF]
|
|
|
|
|
|
D. Bello, D. J. Shah, G. M. Farah, S. Di Luzio, M. Parker, M. R. Johnson, W. G. Cotts, F. J. Klocke, R. O. Bonow, R. M. Judd, et al. Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing {beta}-Blocker Therapy Circulation, October 21, 2003; 108(16): 1945 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Warner Stevenson The points for pacing J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1460 - 1462. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Okumura, G. Takagi, J.-i. Kawabe, G. Yang, M.-C. Lee, C. Hong, J. Liu, D. E. Vatner, J. Sadoshima, S. F. Vatner, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload PNAS, August 19, 2003; 100(17): 9986 - 9990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Au, E. M. Udris, V. S. Fan, J. R. Curtis, M. B. McDonell, and S. D. Fihn Risk of Mortality and Heart Failure Exacerbations Associated With Inhaled {beta}-Adrenoceptor Agonists Among Patients With Known Left Ventricular Systolic Dysfunction Chest, June 1, 2003; 123(6): 1964 - 1969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bouzamondo, J.-S. Hulot, P. Sanchez, and P. Lechat Beta-blocker benefit according to severity of heart failure Eur J Heart Fail, June 1, 2003; 5(3): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jessup and S. Brozena Heart Failure N. Engl. J. Med., May 15, 2003; 348(20): 2007 - 2018. [Full Text] [PDF]
|
|
|
|
 |
|
 H. J Tangeman and J H. Patterson Extended-Release Metoprolol Succinate in Chronic Heart Failure Ann. Pharmacother., May 1, 2003; 37(5): 701 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade, W. S. Colucci, and K. Swedberg {beta}-Blockers in Chronic Heart Failure Circulation, April 1, 2003; 107(12): 1570 - 1575. [Full Text] [PDF]
|
|
|
|
|
|
T. Simon, M. Mary-Krause, C. Funck-Brentano, Ph. Lechat, P. Jaillon, and on behalf of CIBIS II investigators Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II) Eur. Heart J., March 2, 2003; 24(6): 552 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A P Maggioni, G Sinagra, C Opasich, E Geraci, M Gorini, E Gronda, D Lucci, G Tognoni, E Balli, and L Tavazzi Treatment of chronic heart failure with {beta} adrenergic blockade beyond controlled clinical trials: the BRING-UP experience Heart, March 1, 2003; 89(3): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Krum, E. B. Roecker, P. Mohacsi, J. L. Rouleau, M. Tendera, A. J. S. Coats, H. A. Katus, M. B. Fowler, M. Packer, and for the Carvedilol Prospective Randomized Cumulati Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure: Results From the COPERNICUS Study JAMA, February 12, 2003; 289(6): 712 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Agostoni, M. Guazzi, M. Bussotti, S. De Vita, and P. Palermo Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients Chest, December 1, 2002; 122(6): 2062 - 2067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Staudt, M. Bohm, F. Knebel, Y. Grosse, C. Bischoff, A. Hummel, J. B. Dahm, A. Borges, N. Jochmann, K. D. Wernecke, et al. Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy Circulation, November 5, 2002; 106(19): 2448 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Kukin {beta}-Blockers in Chronic Heart Failure: Considerations for Selecting an Agent Mayo Clin. Proc., November 1, 2002; 77(11): 1199 - 1206. [Abstract] [PDF]
|
|
|
|
 |
|
 J. R. R. Heyen, E. R. Blasi, K. Nikula, R. Rocha, H. A. Daust, G. Frierdich, J. F. Van Vleet, P. De Ciechi, E. G. McMahon, and A. E. Rudolph Structural, functional, and molecular characterization of the SHHF model of heart failure Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1775 - H1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Spyrou, S. D. Rosen, F. Fath-Ordoubadi, R. Jagathesan, R. Foale, J. S. Kooner, and P. G. Camici Myocardial beta-adrenoceptor densityone month after acute myocardial infarctionpredicts left ventricular volumes at six months J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1216 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wikstrand, A. k. Hjalmarson, F. Waagstein, B. j. Fagerberg, S. Goldstein, J. Kjekshus, H. Wedel, and MERIT-HF Study Group Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF) J. Am. Coll. Cardiol., August 7, 2002; 40(3): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Bobadilla Current research on carvedilol in heart failure Crit. Care Nurse, August 1, 2002; 22(4): 14 - 16. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Pritchett and M. M. Redfield {beta}-Blockers: New Standard Therapy for Heart Failure Mayo Clin. Proc., August 1, 2002; 77(8): 839 - 846. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Hare Cardiac-Resynchronization Therapy for Heart Failure N. Engl. J. Med., June 13, 2002; 346(24): 1902 - 1905. [Full Text] [PDF]
|
|
|
|
|
|
C. Zugck, A. Haunstetter, C. Kruger, R. Kell, D. Schellberg, W. Kubler, and M. Haass Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1615 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Lowes, E. M. Gilbert, W. T. Abraham, W. A. Minobe, P. Larrabee, D. Ferguson, E. E. Wolfel, J. Lindenfeld, T. Tsvetkova, A. D. Robertson, et al. Myocardial Gene Expression in Dilated Cardiomyopathy Treated with Beta-Blocking Agents N. Engl. J. Med., May 2, 2002; 346(18): 1357 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Taccetta-Chapnick Using Carvedilol to Treat Heart Failure Crit. Care Nurse, April 1, 2002; 22(2): 36 - 58. [Full Text] [PDF]
|
|
|
|
|
|
P. Merlet, L. Hittinger, J. L. Dubois-Rande, and A. Castaigne Myocardial Adrenergic Dysinnervation in Dilated Cardiomyopathy: Cornerstone or Epiphenomenon? J. Nucl. Med., April 1, 2002; 43(4): 536 - 539. [Full Text] [PDF]
|
|
|
|
|
|
B. Riegel, B. Carlson, Z. Kopp, B. LePetri, D. Glaser, and A. Unger Effect of a Standardized Nurse Case-Management Telephone Intervention on Resource Use in Patients With Chronic Heart Failure Arch Intern Med, March 25, 2002; 162(6): 705 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Foody, M. H. Farrell, and H. M. Krumholz {beta}-Blocker Therapy in Heart Failure: Scientific Review JAMA, February 20, 2002; 287(7): 883 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Farrell, J. M. Foody, and H. M. Krumholz {beta}-Blockers in Heart Failure: Clinical Applications JAMA, February 20, 2002; 287(7): 890 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nohria, E. Lewis, and L. W. Stevenson Medical Management of Advanced Heart Failure JAMA, February 6, 2002; 287(5): 628 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Massie Neurohormonal blockade in chronic heart failure: How much is enough? can there be too much? J. Am. Coll. Cardiol., January 2, 2002; 39(1): 79 - 82. [Full Text] [PDF]
|
|
|
|
 |
|
 S.M. DALLABRIDA and M.A. RUPNICK Vascular Endothelium in Tissue Remodeling: Implications for Heart Failure Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 417 - 428. [Abstract] [PDF]
|
|
|
|
|
|
S. Reiken, M. Gaburjakova, J. Gaburjakova, K.-l. He, A. Prieto, E. Becker, G.-h. Yi, J. Wang, D. Burkhoff, and A. R. Marks {beta}-Adrenergic Receptor Blockers Restore Cardiac Calcium Release Channel (Ryanodine Receptor) Structure and Function in Heart Failure Circulation, December 4, 2001; 104(23): 2843 - 2848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lindenfeld, A. D. Robertson, B. D. Lowes, M. R. Bristow, and for the MOCHA Investigators Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1950 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stellbrink, O.-A. Breithardt, A. Franke, S. Sack, P. Bakker, A. Auricchio, T. Pochet, R. Salo, A. Kramer, and J. Spinelli Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1957 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kubo, E. R. Azevedo, G. E. Newton, J. D. Parker, and J. S. Floras Lack of evidence for peripheral alpha1- adrenoceptor blockade during long-term treatment of heart failure with carvedilol J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1463 - 1469. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||